Completed PHASE4 INTERVENTIONAL 2-arm NCT01706510

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease

Sponsor: AstraZeneca

Conditions Coronary Artery Disease

Interventions Clopidogrel Ticagrelor

Updated 6 times since 2017 Last updated: May 4, 2015 Started: Dec 31, 2012 Primary completion: Mar 31, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01706510, this PHASE4 trial focuses on Coronary Artery Disease and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Rapid City Regional Hospital, Inc

Data source: Rapid City Regional Hospital, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rapid City, United States